Magle Chemoswed Holding AB (publ)
MAGLE
Rank in Stocks
#33352
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the... Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Share Price
$0.02547704
Last synced: 2026-11-12
Market Cap
$526.08K
Change (1 day)
-1.00%
Change (1 year)
-98.68%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Magle Chemoswed Holding AB (publ) (MAGLE)
Category
Healthcare
Operating Margin for Magle Chemoswed Holding AB (publ) (MAGLE)
Operating Margin as of November 2026 TTM: -47.21%
According to Magle Chemoswed Holding AB (publ)'s latest financial reports, its current operating margin (TTM) is -47.21%. At the end of 2025 the company had an operating margin of -48.06%.
Operating Margin history for Magle Chemoswed Holding AB (publ) from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -47.21% | -1.77% |
| 2025 | -48.06% | -588.41% |
| 2024 | 9.84% | -6.91% |
| 2023 | 10.57% | 20.52% |
| 2022 | 8.77% | 122.59% |
| 2021 | 3.94% | 74.34% |
| 2020 | 2.26% | 79.37% |
| 2019 | 1.26% | -134.33% |
| 2018 | -3.67% | -341.45% |
| 2017 | 1.52% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | -100.72% |
US
|
|
| -116.04% | -97.54% |
US
|
|
| 25.57% | -100.54% |
AU
|
|
| 31.23% | -100.66% |
BE
|
|
| 29.35% | -100.62% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Magle Chemoswed Holding AB (publ)'s operating margin
What is Magle Chemoswed Holding AB (publ)'s operating margin?
Magle Chemoswed Holding AB (publ)'s operating margin is -47.21%, as of Nov 2026.
What was Magle Chemoswed Holding AB (publ)'s operating margin in 2025?
In 2025, Magle Chemoswed Holding AB (publ)'s operating margin was -48.06%, compared with 9.84% in 2024.
How has Magle Chemoswed Holding AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Magle Chemoswed Holding AB (publ)'s operating margin was highest in 2023 (10.57%) and lowest in 2025 (-48.06%).
How does Magle Chemoswed Holding AB (publ)'s operating margin compare with similar companies?
Magle Chemoswed Holding AB (publ)'s operating margin (-47.21%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.